SLC16A4 and lung carcinoma: Due to the upregulation of the candidate biomarker XAGE1A in lung cancer tissues, which is inconsistent with its downregulated expression in plasma (Figure S2), we initially chose another candidate biomarker SLC16A4 for further analysis.